Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Respiratory Aspiration 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 241Carboplatin 170Injections 139Paclitaxel 122Gemcitabine 118Bevacizumab 117Cisplatin 108Pemetrexed 80Docetaxel 80Cyclophosphamide 74Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 60Nivolumab 55Cetuximab 53fludarabine 52Leucovorin 51130-nm albumin-bound paclitaxel 50Dexamethasone 46Rituximab 41atezolizumab 38venetoclax 35toripalimab 35Drug Therapy 35enzalutamide 32Prednisone 32Letrozole 32Irinotecan 32durvalumab 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × Inhalation × Clear all
NCT06896890 2025-03-26

Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer

Inhatarget Therapeutics

Phase 1/2 Recruiting
32 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Respiratory Aspiration

Data powered by HemOnc (CC BY 4.0) Colophon âš¡